Compare ICCC & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICCC | ECOR |
|---|---|---|
| Founded | 1982 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.5M | 50.0M |
| IPO Year | 1995 | 2018 |
| Metric | ICCC | ECOR |
|---|---|---|
| Price | $6.43 | $5.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 12.2K | ★ 59.2K |
| Earning Date | 03-04-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.33 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | $26,493,169.00 | ★ $32,032,000.00 |
| Revenue This Year | N/A | $34.03 |
| Revenue Next Year | N/A | $30.42 |
| P/E Ratio | $32.60 | ★ N/A |
| Revenue Growth | ★ 51.64 | 27.20 |
| 52 Week Low | $4.52 | $4.16 |
| 52 Week High | $7.60 | $8.55 |
| Indicator | ICCC | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 46.52 | 40.23 |
| Support Level | $6.20 | $4.66 |
| Resistance Level | $6.79 | $7.87 |
| Average True Range (ATR) | 0.18 | 0.62 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 39.26 | 9.14 |
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.